CROI's big takeaways. Dieffenbach started with the event's plenary discussion, which centered on upcoming prevention options, especially for women.
Aside from Truvada (the first drug approved for use as PrEP) and vaginal rings, long-acting prevention options delivered via injectables were seen as successful in recent studies.
The positive prevention results were mostly the result of increased adherence with injections of cabotegravir, which was recently approved by the Food and Drug Administration for treatment of HIV (sold as ViiV Healthcare's Cabenuva) and is being studied as a prevention option.